**Appendix Table E39. Results from studies assessing the ability of VerifyNow to predict other clinical events in patients with ischemic heart disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author,year****UID****Country****Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Clinical Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., bleeding or no bleeding)** | **No. with outcome status within phenotype group** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)****[statistical test]** | **Adjusted?****[YES/NO/NR]****If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| Kim, 2011{Kim, 2011 5 /id}21786434South KoreaCiLostazol administration before pErcutaneous coronAry intervention for Reduction of periprocedural myonecrosis trial (CLEAR trial) | Clopidogrel+aspirin | VerifyNow | Target-lesion revascularization |  | 6 months | Clopidogrel resistance |  | 2/37 (5%) |  |  | NS vs. next row (chi-square statistics or Fisher ’s exact test) |  |  |  |
|  |  |  |  |  |  | Normal response |  | 1/73 (1%) |  |  |  |  |  |  |
| Marcucci, 2009{Marcucci, 2009 144 /id}19118249ItalyNR | clopidogrel 600 mg LD + 75 mg MD & ASA 500 mg IV LD + 100-325 mg MD | VerifyNow | Target-lesion revascularization | by repeat PCI or CABG | 12 months | high residual platelet reactivity (PRU≥240) | Target-lesion revascularization | 16 (7.3)  | HR=1.48 | 0.78–2.78 | P=0.225(RPR vs no RPR) | NO | NR |  |
|  |  |  |  |  |  | No residual platelet reactivity (PRU<240) |  | 24 (5.2) |  |  |  |  |  |  |
| Patti, 2011{Patti, 2011 22 /id}21256470ItalyAntiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty (ARMYDA)–Bleeding Study (ARMYDA-BLEEDS) | Clopidogrel + aspirin | VerifyNow | 30-day incidence of major TIMI bleeding or signiﬁcant entry-site complications (hematoma > 10 cm in diameter, pseudoaneurysm, or arteriovenous ﬁstula) | NR | Within 1 mo | PRU Q1 (highest inhibition) (n=77) | Yes bleeding | 10.1% | OR, 4.5 (NR whether this is vs. Q4 or vs. Q2-4) | 1.9-25.9 | For incidence, 0.043 vs. next row (Fisher’s exact or chi-square)For OR, 0.01 | NR for incidenceYES for OR: age, sex, BMI, DM, stable angina vs ACS, chronic renal failure, hemoglobin levels, previous TIA or stroke, previous major bleeding, use of bivalirudin vs. unfractionated heparin, and use of glycoprotein IIb/IIIa inhibitors | NR | NONE |
|  |  |  |  |  |  | PRUQ4 (n=79) |  | 1.3% | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | PRU Q3 (n=77) |  | 1.4% | NR | NR | 0.05 vs. first row (Fisher’s exact or chi-square) | NR | NR |  |
|  |  |  |  |  |  | PRU Q2 (n=77) |  | 6.3% | NR | NR | NR | NR | NR |  |
| Park, 2011 {Park, 2011 1 /id} 22152948KoreaNR | clopidogrel LD 300 or 600 mg>=12h before PCI, MD 75mg/dayaspirin LD 200mg, MD 100-200 mg/day | VerifyNow | revascularization | revascularization | 2-year | HTPR (PRU >235 and/or a % inhibition <15%) | revascularization | high 78/1660 (4.3) | HR=0.94 | 0.67-1.31 | 0.71comparing with normal cox proportional model  | NR | NR |  |
|  |  |  |  |  |  |  |  | normal 62/1189(5.1) |  |  |  |  |  |  |
| Park, 2011{Park, 2011 18181 /id}21880289KoreaCROSS-VERIFY | clopidogrel LD 300 or 600 mg, MD 75mg/day; aspirin MD 100 mg/day | VerifyNow | Target vessel revascularization | any repeat percutaneousintervention or surgical bypass of any segment of the targetvessel | 1 year | high OPR (HOPR) ≥235 PRUn=407 | MACE | 10 (2.6%) | NR | NR | P=0.861(HOPR vs no HOPR)Log rank test | NR | NR |  |
|  |  |  |  |  |  | No HOPR <235 PRUn=402 |  | 1 (0.3%) |  |  |  |  |  |  |
| Mangiacapra, 2012{Mangiacapra, 2012 18179 /id}22440493Italy & BelgiumARMYDA-PROVE | Clopidogrel LD: 600 mg loading dose ≥6 h before PCI or 75 mg/d x 5 daysClopidogrel MD: 75 mg/d from 4 weeks to 12 monthsAspirin 80-100 mg/day | VerifyNow | Target vessel revascularization | Target vessel revascularization | 30 days | Low PR (PRU ≤178)n = 248  | Target vessel revascularization | 1 (0.4%) | NR | NR | P for trend =0.041  | No | NR |  |
|  |  |  |  |  |  | Normal PR (PRU between ≥179 and ≤238) n = 244 |  | 0 (0%) | OR=0.15(calculated) | 0.009-2.71 | normal vs other |  |  |  |
|  |  |  |  |  |  | High PR (PRU ≥239)n = 240 |  | 5 (2.1%) |  |  |  |  |  |  |
|  |  |  | Hematoma>10 cms | Hematoma>10 cms | 30 days | Low PR (PRU ≤178)n = 248  | Hematoma>10 cms | 19 (7.7%) | NR | NR | P for trend <0.001  | No | NR |  |
|  |  |  |  |  |  | Normal PR (PRU between ≥179 and ≤238) n = 244 |  | 6 (2.5%) |  |  |  |  |  |  |
|  |  |  |  |  |  | High PR (PRU ≥239)n = 240 |  | 3 (1.3%) |  |  |  |  |  |  |